Head-To-Head Survey: Infinity Pharmaceuticals (NASDAQ:INFI) and CV Sciences (NASDAQ:CVSI)

CV Sciences (OTCMKTS:CVSI) and Infinity Pharmaceuticals (NASDAQ:INFI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Risk and Volatility

CV Sciences has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for CV Sciences and Infinity Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CV Sciences 0 2 2 0 2.50
Infinity Pharmaceuticals 0 1 2 0 2.67

CV Sciences presently has a consensus price target of $1.13, suggesting a potential upside of 126.89%. Infinity Pharmaceuticals has a consensus price target of $2.17, suggesting a potential upside of 102.49%. Given CV Sciences’ higher probable upside, equities research analysts clearly believe CV Sciences is more favorable than Infinity Pharmaceuticals.

Valuation and Earnings

This table compares CV Sciences and Infinity Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CV Sciences $53.70 million 0.93 -$16.61 million ($0.17) -2.94
Infinity Pharmaceuticals $3.05 million 20.65 -$47.06 million ($0.83) -1.29

CV Sciences has higher revenue and earnings than Infinity Pharmaceuticals. CV Sciences is trading at a lower price-to-earnings ratio than Infinity Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

0.0% of CV Sciences shares are owned by institutional investors. Comparatively, 47.2% of Infinity Pharmaceuticals shares are owned by institutional investors. 14.6% of CV Sciences shares are owned by company insiders. Comparatively, 13.8% of Infinity Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


This table compares CV Sciences and Infinity Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CV Sciences -51.38% -66.63% -36.13%
Infinity Pharmaceuticals -2,999.17% -1,358.77% -80.72%


CV Sciences beats Infinity Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

CV Sciences Company Profile

CV Sciences, Inc. operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. This segment provides its hemp extract products in balms, sprays, drops, capsules, gummies, and softgel forms. It also sells raw materials to various customers that produce products for resale into the market in Europe. The Specialty Pharmaceuticals segment develops cannabinoids to treat a range of medical indications. Its product candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreements with Arcus Biosciences, Inc. and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.